NCT07128160Not yet recruiting
Cortical Inhibition in Patients With Multiple Sclerosis
The Relationship Between Neuropsychiatric, Radiological Findings and Cortical Inhibition in Patients With Multiple Sclerosis: A Hospital-based Study
Source: ClinicalTrials.gov · Last updated 17 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
1. To investigate the relationship between corticospinal inhibition and clinical, psychological, and cognitive features in MS patients. 2. To examine the association between corticospinal inhibition and radiological findings, including MRI lesions and white matter damage
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 11 Aug 2025
- Start date
- 1 Nov 2025
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- Assiut University
- Diseases
- Multiple sclerosis
- NCT number
- NCT07128160
What you commit to
- Study type: Observational
- Planned participants: 50
- From 1 Nov 2025 to the primary completion date, 1 Nov 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Medications known to alter the corticospinal excitability.
Other illness
- Presence of other neurological or psychiatric disorders (e.g., major depression, bipolar disorder, schizophrenia).
- History of alcohol or substance abuse.
- Contraindications to MRI (e.g., pacemakers, metallic implants) and TMS (i.e., history of seizures, presence of ferromagnetic implants in the head area).
- Severe visual deficit, motor weakness, or intellectual impairment (as per the Mini-Mental State Exam score \< 24).
Who the study is looking for
- Age 18 years or older.
- Diagnosis of RRMS based on the 2017 McDonald Criteria.
- Expanded Disability Status Scale (EDSS) score ≤ 6.5.
- On a stable dose of disease-modifying therapy (DMT) for at least 3 months or naeive patients not use DMT before
- Free of relapses or steroids treatment (at least 3 months after a relapse or corticosteroid therapy)
- Ability to give informed consent and complete neuropsychological assessments.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.